Serum levels of macrophages migration inhibitory factor in patients with coetaneous warts | ||||
Sohag Medical Journal | ||||
Article 27, Volume 21, Issue 2, July 2017, Page 85-90 PDF (77.12 K) | ||||
Document Type: Original Article | ||||
DOI: 10.21608/smj.2017.53647 | ||||
View on SCiNiTO | ||||
Authors | ||||
ESSAMELDIN ABDELAZIZ NADA ; Hanan Assaf; Mohammed Ali; Amaal Mohammed | ||||
DERMATOLOGY, Venereology and Andrology, Faculty of Medicine , sohag university | ||||
Abstract | ||||
Background Coetaneous warts are benign papillomas of the skin of which common warts and plantar warts are the most common types. Up to one third of primary school children have coetaneous warts. Warts are caused by infection with human papillomavirus (HPV) Objective to investigate the serum levels of MIF in patients with coetaneous wartsfrom the outpatient clinic of the Dermatology and Venereology Department, Nag- Hamady general hospital during the period from 1-1-2015 to 1-1- 2016 Results This study included 50 patients with clinical evidence of different types of coetaneous warts and 20 healthy control participants. In this study, there was a statistically significant difference between serum levels of MIF in the patients and controll subject p value= 0.02). The serum levels of MIF were lower in the patients than control subjects Conclusion It is study concluded that there was statistically significant low serum levels of MIF in patients with different types of coetaneous warts compared with healthy participants | ||||
Supplementary Files
|
||||
References | ||||
11. George M. and Vaughan J. In vitro cell migration as a model for delayed hypersensitivity. Proc. Soc. Exp. Biol. Med. 1962; 111: 514-21.
12. Calendra T and Bucala R. Macrophage migration inhibitory factor (MIF): a glucocorticoid counter- regulator within the immune system, Critical Reviews in Immunology. 1997; 17: 77–88.
13. Schober A, Bernhagen J and Bernhagen J. ―Stabilization of therosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice Circulation. 2004 ; 109:380–385.
14. Gregory J. L., Morand E. F., McKeown SJ, Ralph JA, Hall P and Yang YH. ―Macrophage migration inhibitory factor induces macrophage recruitment via CC chemokine ligand 2,‖ Journal of Immunology. 2006; 77: 8072–8079.
15. Nishihira J, Ishibashi T and Fukushima T . Macrophage migration inhibitory factor (MIF): Its potential role in tumor growth and tumor- associated angiogenesis. Ann N Y Acad Sci. 2003; 995: 171-2.
16. Calandra T, Bernhagen J, Metz C. N, Spiegel L. A, Bacher M andDonnelly T. MIF as a glucocor-ticoid-induced modulator of cytokine production. Nature. 1995; 377, 68–71.
17. Bucala R and Donnelly SC. Macrophage migration inhibitory factor: a probable link between inflammation and cancer. Immunity. 2007; 26: 281-5.
18. Abe R, Peng T, Sailors J, Bucala R and MetzCN . Regulation of the CTL response by macrophage migration inhibitory factor. Journal of Immunology.2001; 166:747–753. | ||||
Statistics Article View: 198 PDF Download: 222 |
||||